Calibrium was a biopharmaceutical company developing novel peptide drug candidates for diabetes, obesity, and related metabolic diseases
Calibrium was a biopharmaceutical company developing novel peptide drug candidates for diabetes, obesity, and related metabolic diseases. Novo Nordisk acquired the company in 2015.